On March 30, the launching meeting for the multi-center clinical trial of cerebral vein thrombectomy device, jointly developed by Xuanwu Hospital, affiliated to Capital Medical University, and Beijing Honghai Minimally Invasive Technology Co., Ltd. (a client of Qihang Funds under the Group), was held in Beijing.

The trial was sponsored by Beijing Honghai Minimally Invasive Technology Co., Ltd. and the research work was undertaken mainly by Professor Ji Xunming, and his research team from Xuanwu Hospital affiliated to Capital Medical University. 

Beijing Honghai，founded in 2017, focuses on the R&D and industrialization of medical devices for nerve intervention and peripheral vascular intervention, and is committed to providing a series of interventional device solutions for patients with cerebral artery/vein and peripheral artery/vein vascular diseases.

As one of the earliest technical groups performing R&D of interventional products in China, its core technical team has more than 20 years of experience in the R&D and industrialization of vascular intervention products.

Not long ago, Beijing Honghai obtained the A-round financing worth tens of millions yuan, led by Qihang Funds under ZGC Development Group, which is mainly used for the R&D of products, such as cerebral vein thrombectomy stent and intracranial vein stent.

The medical device entering into the clinical trial is the result of 10-years joint efforts of Beijing Honghai and Xuanwu Hospital, therefore they own independent IP rights of the device.

The device is specifically designed for cerebral sinus thrombosis. Compared with traditional therapy, it has great advantages in terms of operation convenience, treatment effect and safety.